Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.38 |
| ▸ | MAOB | P27338 | 6/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268256 | 0.76 | MAPKAPK2 (0.39) | MAOBHTR2AHTR2B | |
| SCHEMBL31547780 | 0.76 | HTR2C (0.49) | MAOBHTR2B | |
| SCHEMBL25030186 | 0.75 | HDAC3 (0.49) | MAOBMTNR1AHDAC3HDAC4HDAC1 | |
| SCHEMBL25030182 | 0.74 | MTNR1A (0.33) | MPOMTNR1A | |
| SCHEMBL1727808 | 0.74 | HTR2B (0.51) | MPOMAOBHTR2B | |
| SCHEMBL25029606 | 0.73 | HTR2A (0.58) | HTR2AHTR2BHTR6 | |
| SCHEMBL2269457 | 0.73 | MAPT (0.43) | MAOBHTR2B | |
| SCHEMBL1727095 | 0.72 | ATM (0.40) | MAOBHTR2AHTR2B | |
| SCHEMBL1727408 | 0.71 | GFER (0.41) | MAOBHTR2B | |
| SCHEMBL1726725 | 0.71 | HTR2B (0.41) | MAOBHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | Kuleon, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | Kuleon, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | Kuleon, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | Kuleon, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023018864-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | HTR2C, HTR2A, HTR3C | MPO 4717/4885MAOB 129/4885HTR2A 2/4885 |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | HTR2C, HTR2A, HTR3B | MPO 3274/4885MAOB 160/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.